New Trial CABOGIST now open

IKCC Studien Design Avelumab V5

Cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib.

Trial name: CABO-GIST (see more information on our study registry)

Agents: Cabozantinib

Phase: II

Status: Open, recruiting

Sponsor: European Organisation for Research and Treatment of Cancer – EORTC

Further information or

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.